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A boy with myelomeningocele who had sigmoidocolocystoplasty and ureteric reimplantation when 2-
years old and normal annual cystoscopies, developed hematuria and abdominal pain with liver
dysfunction 14 years postoperatively. Computed tomography showed a tumor on the left side of the
augmented bladder, a large lymph node, and large multiple probable metastases in the liver. Cystoscopy
3 months earlier had been normal, but when repeated showed a tumor originating from the augmented
sigmoid colon. Biopsy showed undifferentiated sarcoma. Despite chemotherapy, he died 3 months later.
The diagnosis at autopsy was undifferentiated sarcoma originating from the sigmoid colon. We report
the ﬁrst case of undifferentiated sarcoma developing 14 years after sigmoidocolocystoplasty for
meningomyelocele, and also review the 55 cases of post-bladder augmentation malignancy in the
literature.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Since Mikuliz’s [1] report published in 1899, the indications for
enterocystoplasty (ECP) using colon, ileum, or stomach, have
expanded dramatically, and ECP has become an accepted
reconstructive option for intractable incontinence and poor
bladder compliance in many neurogenic and non-neurogenic
disorders [2].
However, recently, there have been an increasing number of
reports of benign and malignant tumors developing in the neo-
bladder in post-ECP patients on long-term follow-up, especially
around the line of anastomosis between the colon cap and the
native bladder remnant [2]. On histopathology, the malignant tu-
mors identiﬁed were adenocarcinoma, transitional cell carcinoma,
and malignant sarcoma.
We have performed 120 sigmoidocolocystoplasties over the past
30 years in our departments. Of these, one case developed sarcoma
at the patch site of the sigmoidocolocystoplasty. We report this casestinal and Pediatric Surgery,
injuku-ku, Tokyo 160-0023,
hi).
Inc. This is an open access article uand review the literature for post bladder augmentation
malignancies.
1. Case report
A 16-year-old boy was hospitalized after becoming febrile with
hematuria, dysuria, general fatigue, and right upper quadrant pain.
He was born with myelomeningocele and neurogenic bladder with
bilateral ureterovesical junction stenosis, bilateral hydroureter and
hydronephrosis, bilateral renal dysfunction, and low bladder
compliance. He underwent sigmoidocolocystoplasty and bilateral
ureteric reimplantation when he was 2-years old.
On admission, white cell count (7800/mL), C-reactive protein
(8.3 mg/dL), and transaminase (AST: 83 IU/L, ALT: 57 IU/L) were
elevated among the laboratory data. However, tumor markers
such as a-fetoprotein, carcinoembryonic antigen, and carbohy-
drate antigen 19-9 were not elevated. Computed tomography
showed a tumor on the left side of the augmented bladder,
swelling of the lymph nodes in the pelvic cavity, and large mul-
tiple probable metastases in the liver (Fig. 1a and b). Cystoscopy 3
months earlier had been normal, but when repeated showed a
tumor originating from the augmented sigmoid colon (Fig. 2).
Histopathology revealed that the tumor was composed of smallnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computed tomography images of the patient. a: Image of the patient’s bladder, displaying thickening of the bladder wall (arrow). b: Image of the patient’s liver, displaying
large multiple masses (arrows).
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negatively for cluster of differentiation 99 (also known as MIC-2),
desmin, myoglobin, smooth muscle actin, S-100, chromogranin,
cluster of differentiation 56, neuron speciﬁc enolase, synapto-
physin, cluster of differentiation 34, and podoplanin (a 38-kDa
O-linked transmembrane sialoglycoprotein recognized by the
D2-40 antibody). From these ﬁndings, a diagnosis of undifferen-
tiated sarcoma was made.
The tumor grew rapidly, and his general condition worsened.
The multiple liver metastases ruptured repeatedly and his condi-
tion was thought to be beyond surgical cure. Chemotherapy was
therefore commenced.
We initially selected vincristine, actinomycin D, and cyclo-
phosphamide (VAC) therapy, because the tumor was histopatho-
logically similar to rhabdomyosarcoma. However, when we
evaluated the efﬁcacy of the chemotherapy by computed tomog-
raphy, 9 days after the start of chemotherapy, we found that the
size of the liver metastasis had increased. Therefore, we concluded
that VAC therapy was not effective and changed to ifosfamide and
etoposide (IE) therapy, which is used for the treatment of Ewing
sarcoma. However, intratumoral hemorrhage occurred during the
course of chemotherapy, and his general condition worsened.
From that time, he developed jaundice, breathing failure due toFig. 2. Diagram of cystoscopic ﬁndings prior to commencing treatment for the ma-
lignancy. A tumor was identiﬁed in the left side of the augmented bladder. The tumor
existed away from the anastomosis, between the sigmoid colon cap and the native
bladder. There were no malignant changes in the native bladder, including in the
ureteric oriﬁces.the abdominal distension, and systemic edema. IE therapy was
ineffective and we changed his treatment to cisplatin and Adria-
mycin. However, this was also ineffective and he died 3 months
later from multiple organ failure (Fig. 4). The diagnosis at autopsy
was undifferentiated sarcoma originating from the sigmoid colon
(Fig. 5).2. Literature review
To the best of our knowledge, there are 55 cases of malignancy
occurring after bladder augmentation reported in the literature
(Table 1). The sex distribution was 24 male patients (44%), 16 fe-
male patients (29%), and 15 undescribed patients (27%). Age at ECP
ranged from 5 to 59 years (mean: 31 years), with 7 cases receiving
ECP when less than 15 years old (13%); 7 between 16 and 20 years
old (13%), 10 between 21 and 30 years old (18%), 3 between 31 and
40 years old (5%), 7 between 41 and 50 years old (13%), 8 more
than 50 years old (15%), and 13 not described (24%). Accordingly,
most patients developed malignancy as adults. Duration of follow-
up ranged from 0.25 to 38 years (mean: 19.3), with follow-up for
0e5 years in 5 (10%), 6e10 years in 4 (7%), 11e15 years in 12 (22%),
16e20 years in 10 (18%), and 21e30 years in 13 (24%), 31 or more
in 9 (16%), and not described in 2 (4%). Underlying pathology was
urinary tuberculosis in 17 cases (31%), neurogenic bladder in 15
cases (27%), schistosomiasis in 2 cases (4%), post bladder surgery
in 1 case (2%), and unknown in 20 cases (36%). Bladder augmen-
tation involved the small bowel in 30 cases (55%), colon in 13 cases
(24%), stomach in 8 cases (15%), and ileocecum in 4 cases (7%).
Histopathology conﬁrmed adenocarcinoma in 36 cases (65%),
transitional cell carcinoma in 11 cases (20%), signet ring cell car-
cinoma in 4 cases (7%), squamous cell carcinoma in 2 cases (4%),
oat cell carcinoma in 1 case (2%), and sarcoma after ileocystoplasty
in 1 case (2%). Malignancies arose from the anastomosis in 27
cases (49%), intestinal cap in 10 cases (18%), native bladder in 9
cases (16%), and unknown in 9 cases (16%). Treatment was cys-
tectomy in 38 cases (69%), ileal conduit in 15 cases (27%), ureter-
ostomy in 8 cases (15%), sigmoid conduit in 4 cases (7%),
ileocystoplasty in 3 cases (5%), pelvic exenteration in 2 cases (4%),
transurethral resection in 2 cases (4%), and cecocystoplasty in 1
case (2%).3. Discussion
There have recently been reports of an increased incidence of
malignancy after ECP [2e5], most developing in patients with
tuberculous cystitis. It is well known that malignant epithelial
Fig. 3. Histopathological analysis of the tumor. a: Hematoxylin and eosin staining of the tumor specimen (40). b: A high magniﬁcation image of the tumor (400) showing the
presence of small round tumor cells.
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the small bowel. However, Husmann et al. [6] reported that the
incidence of carcinoma in patients with colonic-vesical augmen-
tation was almost equal to the risk of developing colonic adeno-
carcinoma of the bowel in the general population. They also
reported that the incidence of carcinoma in patients with ileal-
vesical augmentationwas 40e50 folds higher than the incidence of
developing carcinoma in the small bowel.
Filmer and Spencer [5] reported an increased incidence of ma-
lignancy in patients whose bladders were augmented for benign
disease. Urinary acidity, bacterial generation of nitrosamines in
urine, and local inﬂammatory responses in the bowel mucosa
chronically exposed to urine have been proposed as possible
mechanisms for carcinogenesis. However, we previously reported
that metaplasia or hyperplasia identiﬁed during follow-up can be
managed effectively by more frequent and thorough bladder irri-
gations to control inﬂammation [2].
Primary sarcomas of the bladder are uncommon, constituting
only about 0.5% of all bladder tumors [7]. There is only 1 report of
undifferentiated sarcoma developing after ileocystoplasty, and
this is the ﬁrst report of sarcoma developing after sigmoidoco-
locystoplasty. The etiology and relationship between bladderFig. 4. Clinical course of the patient. A diagram showing the clinical course of the
patient. Biopsy was performed on the fourth day after admission. Severe intrahepatic
hemorrhage occurred on day 9 and day 45. The patient died 92 days after admission.
The rectangles indicate the time during which the therapies indicated within the
rectangles were performed. The triangles indicate the time during which the indicated
symptoms were observed, and their worsening with time. VAC: vincristine, actino-
mycin D, and cyclophosphamide therapy, IE: ifosfamide and etoposide therapy, CDDP:
cisplatin, ADR: Adriamycin.augmentation and sarcoma are not clear. Our patient may have
developed a sarcoma at the site of sigmoidocolocystoplasty, had
a colonic sarcoma in the sigmoid colon segment that was used
for the augmentation cystoplasty, or irritation from urine could
have caused the tumor to develop. No obvious cause was
identiﬁed.
Hamid et al. [8] reported that they perform yearly surveillance
cystoscopy in patients who received augmentation or substitution
ECP more than 10 years earlier. We also performed annual cysto-
scopic evaluation and biopsy. However, malignancy has beenFig. 5. Photograph of the autopsy specimen. The tumor originated from the sigmoid
colon cap. The solid yellow line delineates the tumor. The dotted blue line delineates
the border between the native bladder and the colon cap.
Table 1
Post bladder augmentation malignancy cases in the literature.
Cases (%)
Sex
Male patient 24 (44%)
Female patient 16 (29%)
ND 15 (27%)
Age at ECP (yrs)
<15 7 (13%)
16e20 7 (13%)
21e30 10 (18%)
31e40 3 (5%)
41e50 7 (13%)
>51 8 (15%)
ND 13 (24%)
Duration of FU (yrs)
<5 5 (10%)
6e10 4 (7%)
11e15 12 (22%)
16e20 10 (18%)
21e30 13 (24%)
>31 9 (16%)
ND 2 (4%)
Underlying pathology
Tuberculosis 17 (31%)
Neurogenic bladder 15 (27%)
Schistosomiasis 2 (4%)
Post bladder surgery 1 (2%)
ND 20 (36%)
Selection of bowel
Small bowel 30 (55%)
Colon 13 (24%)
Stomach 8 (15%)
Ileocecum 4 (7%)
Histopathology
Adenocarcinoma 36 (65%)
TCC 11 (20%)
Signet ring cell carcinoma 4 (7%)
Squamous cell carcinoma 2 (4%)
Oat cell carcinoma 1 (7%)
Sarcoma 1 (2%)
Location
Anastomosis 27 (49%)
Intestinal cap 10 (18%)
Native bladder 9 (16%)
ND 9 (16%)
ND: not described, ECP: enterocystoplasty, FU: follow up, yrs: years,
TCC: transitional cell carcinoma.
Y. Hayashi et al. / J Ped Surg Case Reports 3 (2015) 385e388388detected in all ECP patients secondary to the development of
symptoms, and not as a result of regular surveillance cystoscopy
[3,9].
4. Conclusions
This is the ﬁrst report of sarcoma developing after sigmoidoco-
locystoplasty; however, the etiology is unclear. Surgeons should be
aware of the possibility of malignant changes in all patients with
bladder augmentation.
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